/NOT FOR DISTRIBUTION TO
The following nominees were elected as directors of Willow for the ensuing year, with the specific voting results being as follows:
Votes For | Votes Withheld | |||
Director | # | % | # | % |
Dr. Peter Seufer- Wasserthal | 34,517,839 | 99.99% | 3,735 | 0.01% |
34,517,839 | 99.99% | 3,735 | 0.01% | |
Dr. | 34,517,839 | 99.99% | 3,735 | 0.01% |
34,517,839 | 99.99% | 3,735 | 0.01% | |
34,517,834 | 99.99% | 3,740 | 0.01% | |
34,517,834 | 99.99% | 3,740 | 0.01% |
In addition, shareholders approved the appointment of
Shareholders also ratified and approved the adoption of a new stock option plan of the Company and authorized its continuation for a three-year period from the date of the Meeting (99.95% of the votes cast being in favour).
About
Willow is a Canadian biotechnology company based in
Reader Advisories
This news release may include forward-looking information that involves risk and uncertainty. For this purpose, any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements often contain terms such as "may", "will", "should", "anticipate", "expects" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Willow assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
SOURCE
© Canada Newswire, source